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Summary
 Aim The proliferative potential, and DNA ploidy in 50 brain tumours (15 grade I & II, 
and 35 grade III & IV astrocytomas) were investigated using bromodeoxyuridine 
(BrdUrd) incorporation and ﬂ ow cytometry.
 Materials/Methods Tumour samples taken from each patient during surgery were incubated in vitro 
for one hour at 37°C with bromodeoxyuridine (BrdUrd), using the high pres-
sure oxygen method. The percentage of BrdUrd-labelled cells (BrdUrd Labelling 
index, BrdUrd LI), and the total DNA content were evaluated. After surgery, 21 
patients received conventionally fractionated radiotherapy (RT), 11 patients re-
ceived accelerated RT, and 18 patients underwent hypofractionated RT.
 Results The tumours showed variability in BrdUrd LI values, which ranged from 0.3 to 
15.8%. A signiﬁ cantly higher mean value for BrdUrd LI was shown in grades 
AIII & IV (3.5%), than in astrocytomas of grades AI & II (1.5%, p=0.005). A 
lower though not statistically signiﬁ cant percentage of DNA aneuploidy was ob-
served in low-grade (40.2%) glioma than was seen in high-grade (65.7%) glio-
ma. Univariate analysis showed that younger (≤50 years) patients (p=0.001), those 
with AI & II glioma (p=0.000), low tumour proliferation rate (BrdUrd LI ≤2.1%, 
p=0.006) and conventional or hypofractionated RT (p=0.000) had a signiﬁ cant-
ly higher 5-year survival rate. Tumour ploidy had no inﬂ uence on patients’ sur-
vival (p=0.261). However, a Cox multivariate analysis showed that only the pa-
tients’ age (>50 years), high grade tumours (AIII & IV) and accelerated RT were 
signiﬁ cantly unfavourable prognostic factors in terms of survival.
 Conclusions To improve RT results, younger patients (≤50 years) with fast proliferating tu-
mours should receive more aggressive treatment.
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BACKGROUND
The results of treatment in cases of cerebral glial 
tumours, in spite of continuous development and 
improvement in treatment protocols, are still not 
satisfactory. However, in the last decade, 5-year 
survival rates in patients with gliomas increased 
due to improvements in surgical techniques, ra-
diotherapy (RT) and chemotherapy. It is suggest-
ed that further improvements will be the result 
of research into the molecular genetic features of 
brain tumours [1]. Therefore, the ability to pre-
dict the response to treatment and patients’ sur-
vival, based on the biological parameters of the tu-
mours, would be useful in clinical practice. One of 
the most frequently investigated factors is the pro-
liferative potential of tumour cells, as this parame-
ter may be used in the selection of more aggressive 
treatments [2] and may predict recurrence rate 
[3]. Many methods for the assessment of prolifer-
ative potential have been used, including: mitosis 
count, AgNOR count, the Ki-67 or PCNA labelling 
index – indicating cells in all phases of the cell cy-
cle except the G0 phase, S phase fraction bromo-
deoxyuridine labelling index (BrdUrd LI) which 
identiﬁ es cells actively synthesising DNA and po-
tential doubling time (Tpot), i.e. time required for 
a tumour cell population to double its number in 
the absence of cell loss. In cases of glioma, BrdUrd 
LI, and Tpot are considered the best methods for 
assessing proliferative potential and giving good 
correlation with clinical outcome [4–6]. The treat-
ment of choice, in low advanced astrocytomas, is 
surgical resection with the preservation of neuro-
logical function. However, it has been shown that 
adjuvant RT increases survival time in patients 
with high-grade malignant gliomas [7,8]. A large 
number of factors can potentially inﬂ uence sur-
vival rate, including the patient, the tumour and 
the treatment parameters.
AIM
The aim of this study was to investigate some of 
these factors, paying special attention to biolog-
ical factors of the tumour, such as proliferation 
rate (BrdUrd LI) and DNA ploidy, in patients 
with astrocytic gliomas treated with surgery and 
postoperative radiotherapy (RT).
MATERIALS AND METHODS
Patients
Fifty patients with primary cerebral glial tumours 
were included in the study. There were 26 men 
and 24 women. The mean age of the patients was 
46.8±SD 11.8 (range 20–73) years. There were 15 
patients with low-grade gliomas (AI&AII), 19 pa-
tients with AIII gliomas and 16 patients with AIV 
gliomas according to the Kernohan grade [9].
Treatments
Between the years 1991 and 1997, 50 patients 
were treated with surgery aimed at complete 
removal (Department of Neurosurgery, Colle-
gium Medicum, Jagiellonian University, Kra-
ków, Poland) and postoperative radiotherapy 
with curative intent (Department of Radiation 
Oncology, Centre of Oncology, Kraków, Poland). 
Postoperative radiotherapy was given after a mean 
term of 54 days (23–104). Three schedules of RT 
were applied. Twenty-one patients received con-
ventionally fractionated RT, with 60 Gy in 30 frac-
tions of 2 Gy, 11 patients received accelerated RT 
(53 Gy in 20 fractions over 10 days; two fractions 
per day, and hypofractionated RT with three series 
each of 20 Gy in 5 fractions, separated by 4 week 
intervals was applied in 18 cases. Low-grade glio-
mas were treated with conventional fractionation 
only, AIII gliomas with all three treatment sched-
ules, while AIV gliomas were treated with a twice 
daily or three series schedule (Table 1).
BrdUrd labelling index
The tumour specimens (about 0.5 cm3) from 
each patient, were delivered fresh from the op-
erating room shortly after excision. They were 
cut into small pieces and incubated in vitro with 
BrdUrd for l hour at 37°C in high oxygen pres-
sure. After incubation, tumour fragments were 
ﬁ xed in 70% ethanol. The BrdUrd staining proce-
dure and ﬂ ow cytometry have been described in 
detail elsewhere [10]. To obtain pure nuclei from 
cells, tumour fragments were minced and digested 
at 37°C with 0.4 mg/ml pepsin (Sigma Chemicals, 
Poole, Dorset) in 0. l M HCl for 20 min. The sus-
pension of nuclei was ﬁ ltered through a 35 µm 
nylon mesh and centrifuged at 2000 rpm for 5 
min. Partial DNA denaturation was achieved by 
resuspension of the pellet in 2 M HCl for 10 min. 
The nuclei suspension was then washed twice in 
phosphate-buffered saline (PBS). The pellet was 
further incubated in PBS containing 0.5% nor-
mal goat serum (Sigma Chemicals), 0.5% Tween 
20 (Sigma Chemicals) and a mouse anti-BrdUrd 
monoclonal antibody (DAKO) for one hour. 
After incubation, the nuclei were washed in PBS 
and suspended in PBS/NGS/Tween containing 
goat anti-mouse IgG-FITC conjugate (DAKO) for 
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l hour. Finally, the nuclei suspension was washed 
twice in PBS and stained for total DNA using 10 
µg/ml propidium iodide (PI) in PBS.
Flow-cytometric analysis
The stained material was analysed with a 
FACSCalibur ﬂ ow cytometer (Becton Dickinson 
Immunocytometry Systems, Sunnyvale, CA, USA) 
equipped with an argon-ion laser (488 nm) and op-
erated at 15 mW. Doublets and clumps were exclud-
ed from the analysis by gating on a bivariate distri-
bution of the red peak vs the integral signal. Ten 
to 20 thousand events were collected in each histo-
gram. BrdUrd LI was calculated as the percentage 
of cells which incorporated BrdUrd. In aneuploid 
tumours the diploid subpopulation of labelled cells 
was subtracted. Tumour ploidy was calculated from 
the DNA proﬁ le using ModFit LT software (Verify 
Software House, Inc. USA). Aneuploidy was assessed 
in cases in which the normal and neoplastic cell 
populations gave two separate peaks. DNA index 
was calculated as a ratio of the modal DNA ﬂ uores-
cence of abnormal to normal G1/G0 cells. Human 
lymphocytes were used as a reference peak.
Statistical analysis
All statistical analyses were performed using 
STATISTICA v.5.1 software. Descriptive statis-
tics were used to determine the mean values of 
variables and standard errors of means (SE). In 
all statistical procedures, p values lower than 0.05 
were considered signiﬁ cant. The statistical signif-
icance of the differences between means was as-
sessed by use of the Mann-Witney U test (grade 
vs. age, LI). The probability of survival was calcu-
lated using the Kaplan-Meier method [11]. A uni-
variate analysis was carried out using a log-rang 
test. Median values were used for cut-off points. 
All clinical and biological parameters were en-
tered into the multivariate analysis, which was per-
formed using a Cox proportional hazard model 
and a stepwise regression procedure [12].
RESULTS
Patients with AI or AII gliomas were signiﬁ cantly 
younger than those with AIV gliomas (Table 1). 
Low grade (AI & II) gliomas were seen in 10 men 
and 5 women, while the high-grade (A III & IV) 
group comprised 16 men and 19 women. No dif-
ference in mean age between men and women 
was found (p=0.335). A signiﬁ cant correlation be-
tween tumour grade and patients’ age (p=0.000), 
or tumour grade and RT schedule (p=0.000) was 
demonstrated.
The brain tumours showed variability in the 
BrdUrd LI. The BrdUrd LI ranged from 0.3 to 
Kernohan Grade
Sex
Age (years) Mean (range)
Radiotherapy
M F Conventional Accelerated Hypofractionated
AI 5 3  39.7 (28.0–57.0) 8 0 0
AII 5 2  36.7 (20.0–47.0) 7 0 0
AIII 9 10  48.0 (27.0–73.0) 6 4 9
AIV 7 9  53.4 (29.0–69.0)*,** 0 7 9
All 26 24  46.8 (20.0–73.0) 21 11 18
Table 1. Patients’ characteristics and distribution of clinical and pathological features.
Signiﬁ cant diﬀ erence in mean age between: * AI and AIV gliomas, p=0.004; ** AII and AIV gliomas, p=0.001.
Grade N BrdUrd LI (%) Mean (range) Diploid tumours (%) Aneuploid tumours (%)
AI & AII 15  1.5 (0.4–4.6)  9 (60.0)  6 (40.0) 
AIII & AIV 35  3.5 (0.3–15.8)*  12 (34.3)  23 (65.7)**
All 50  2.9 (0.3–15.8)  21 (42.0)  29 (58.0)
Table 2. Diﬀ erences in biological parameters between AI & AII, and between AIII & AIV gliomas.
* Signiﬁ cant diﬀ erence between AI & AII and AIII & AIV gliomas, p=0.005;
** Signiﬁ cant diﬀ erence between diploid and aneuploid tumours in high-grade gliomas (AIII & AIV), p=0.040.
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15.8% (Table 2). The mean BrdUrd LI for grade 
III and IV gliomas was signiﬁ cantly higher than 
for grade I – II gliomas (Table 2). A correlation 
between tumour grade and BrdUrd LI was found 
(p=0.025).
There were 21 (42%) diploid and 29 (58%) ane-
uploid tumours (Table 2). A higher percentage 
of aneuploidy was observed in AIII & IV (65.7%) 
than AI & II tumours (40%). In the aneuploid 
subpopulation, 18 (36%) of the 29 aneuploid tu-
Figure 1. Negative factors for the survival of glioma patients 
treated with surgery and RT: age (>50 years; A), tumour grade 
(AIII & IV; B), BrdUrd LI (>2.1%; C), DNA ploidy (aneuploidy; D) 
and RT schedule (accelerated; E). The relative number of patients 
surviving in each subgroup is given in parentheses.
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mours were hyperdiploid (DNA index 1.2–1.8), 9 
(18%) were tetraploid (DNA index 1.9–2.1) and 
2 (4%) were hypertetraploid.
Nine (18%) patients survived the 5-year period. 
Kaplan-Meier survival curves were plotted accord-
ing to patients’ age, tumour grade, BrdUrd LI, tu-
mour ploidy and RT schedule. Younger patients 
(≤50 years) survived signiﬁ cantly longer than 
older patients (>50 years; p=0.001, Figure 1A). 
Median survival time for the ﬁ rst group was 28 
months and for the second 11 months (Table 3). 
A higher survival percentage was observed in the 
grades I & II group than in the grades III & IV 
group (p=0.000, Figure 1B). The median surviv-
al time for the ﬁ rst group was 50 months, while 
for the grade III & IV groups it was 11 months 
(Table 3).
The univariate analysis showed that patients 
with slowly proliferating tumours (BrdUrd LI 
≤2.1%) survived signiﬁ cantly longer (p=0.006) 
than those with faster proliferating tumours 
(BrdUrd LI >2.1%) (Figure 1C). Median sur-
vival time for the ﬁ rst subgroup was 30 months 
and for the second group 12 months (Table 3). 
There was no signiﬁ cant difference in patients 
survival with respect to tumour ploidy (p=0.249, 
Figure 1D).
It was shown in the univariate analysis that pa-
tients receiving conventional RT treatment sur-
vived signiﬁ cantly longer than those treated with 
hypo- and accelerated RT (p=0.000, Figure 1E). 
When, instead of schedule RT, a total RT dose of 
<56 Gy >was used (not shown), signiﬁ cantly better 
survival (p=0.005 ) was observed in those patients 
who received RT doses greater than 56 Gy.
All the clinical data were entered into the Cox 
multivariate analysis (patients’ age, tumour grade, 
schedule of RT) along with biological prognostic 
factors (BrdUrd LI and DNA ploidy). The analy-
sis revealed that there were only three unfavour-
able prognostic factors affecting the survival rate 
of the patients: age >50 years (p=0.038), high tu-
mour grade (A III & IV) (p=0.022) and an ac-
celerated schedule of RT (p=0.018, Table 4). As 
the univariate and multivariate analyses revealed 
that age was a strong prognostic factor, we per-
formed separate multivariate analyses for young-
er (≤50 years) and older patients (>50 years). It 
appeared that, for younger patients, signiﬁ cant 
positive prognostic factors with respect to sur-
vival were: conventional or hypofractionated RT 
(p=0.033) and BrdUrd LI (<2.1%). However for 
older patients, none of the analyzed parameters 
had an impact on survival.
DISCUSSION
This study was conducted in order to determine 
whether BrdUrd LI or DNA ploidy can identify 
patients with poorer outcomes, who might bene-
ﬁ t from more aggressive treatments. The BrdUrd 
LI method revealed a variability in proliferative 
potentials for both low and high-grade gliomas 
which may conﬁ rm that this group of tumours 
represents heterogeneous diseases of different 
biological behaviors. Some authors studying cell 
kinetics in gliomas have also used BrdUrd LI to 
identify differences in proliferation rates between 
Parameter N Median survival (months)
(log-rank test) 
p value
Age
 ≤50 years
 >50 years
29
21
28
11 0.001
Grade
 AI & AII
 AIII & AIV
15
35
50
11 0.000
BrdUrd LI
 ≤2.1%
 >2.1%
28
22
30
12 0.006
Ploidy
 diploid
 aneuploid
21
29
19
16 0.261
RT
 Conventional
 Accelerated
 Hypofractionated
21
11
18
37
10
12 0.000
Table 3. Univariate analysis for 50 glioma patients treated with 
surgery and radiotherapy.
Parameter RR (relative risk) p value
Age
 ≤50 years
 >50 years
1.0
2.2 0.038
Grade
 AI & AII
 AIII & AIV
1.0
2.9 0.022
Radiotherapy
 Conventional
 + Hypofractionated
 Accelerated
1.0
2.6 0.018
Table 4. Multivariate Cox analysis for 50 patients (ﬁ nal model).
Rep Pract Oncol Radiother, 2005; 10(5): 231-238 Gasińska A et al – Signiﬁ cance of biological factors in gliomas treated with RT
235
and within groups of brain tumours of different 
histology [5,6,13–15]. In our study, the BrdUrd 
LI for the examined tumours ranged between 
0.3 and 15.8% and high grade gliomas showed 
higher proliferation rates. These values fall with-
in ranges given by other authors for these groups 
of tumours [13,14]. Correlation of tumour cell 
kinetic parameters with post-treatment follow-up 
showed that patients with tumours of lower pro-
liferative potential (BrdUrd LI ≤2.1%) survived 
signiﬁ cantly longer than those with tumours of 
higher proliferative potential (BrdUrd LI >2.1%). 
Several studies on BrdUrd LI in brain tumours 
have shown the signiﬁ cance of that parameter 
in patients’ survival [4,16] and recurrence rate 
[3], indicating a greater probability of survival 
in patients whose tumours had LI’s below 1–3%. 
Also some other studies have revealed a highly 
signiﬁ cant correlation between low S-phase frac-
tion <3% [17], low Ki-67 clone MIB-1 LI [2,18] 
and longer patients’ survival. Our investigation 
showed that the proliferation rate of the tumour 
correlated with its grade. BrdUrd LI appears to 
reﬂ ect the aggressiveness of the tumour, as high-
grade gliomas had signiﬁ cantly higher prolifer-
ation rates. Therefore, this parameter seems to 
be as important in selecting the treatment as 
the histopathological diagnosis and therefore 
should be considered an important factor in de-
termining the prognosis of individual patients 
with brain tumours.
The examined tumours showed a relatively low 
rate of aneuploidy (58%). A lower percentage of 
aneuploidy was recorded for low-grade (40.0%) 
tumours than for high-grade gliomas (65.7%), 
though this difference was not statistically signif-
icant. Our data fell within ranges described by 
other authors (57.3–89.0%) in the case of high-
grade tumours [10,19]. Tetraploid and hyper-
tetraploid tumours were more frequent (24% ) 
in AIII & IV than in low-grade tumours (6.9%), 
and only the high-grade subgroup displayed hy-
pertetraploidy which might be indicative of a 
higher degree of malignancy in these tumours. 
Nevertheless, DNA ploidy was not predictive in 
terms of survival. In the literature, opinions on 
the assessment of DNA ploidy as a prognostic 
factor in brain tumours are inconclusive. Some 
authors considered diploidy to be a prognostic 
factor [19], others did not observe any signiﬁ -
cant association between DNA ploidy and sur-
vival time [4,17,20].
In our series, the age of patients appeared to be 
a signiﬁ cant prognostic factor. As in other stud-
ies [2,4,21,22], younger patients (≤50 years) sur-
vived signiﬁ cantly better than older patients. It 
is known that brain tumours in elderly patients 
seem to have an intrinsic resistance to cancer 
treatment, though there is no clear explanation 
for this fact. The brain may have a unique role in 
the process of aging; differentiated post-mitotic 
neurons are not replaced by cell division and little 
turnover of DNA occurs in glial cells. Moreover, 
cell aging in the brain may be associated with a 
decrease in oxygen uptake [23], which may be 
related to lower levels of cytotoxic free radicals 
under irradiation. Alternatively, the difference 
may lie with scavenging enzymes that neutralize 
or inactivate nucleophilic molecules. Rosenblum 
et al. [24] have shown that patients’ age inversely 
correlates with in vitro cell kill from biopsies, and 
that patients with sensitive cells were signiﬁ cant-
ly younger than those with resistant cells. Older 
people may have accumulated genetic damage 
throughout their lives, which is linked with expo-
sure to exogenous mutagens and a possible de-
crease in various host functions, such as DNA re-
pair and other defence mechanisms [25].
Malignant gliomas are among the most devastat-
ing cancers, commonly producing profound and 
progressive disability, and leading to death in most 
cases. The inﬁ ltrating nature of high-grade glio-
mas makes complete resection virtually impossi-
ble. Thus, standard treatment generally consists 
of cytoreductive surgery followed by radiothera-
py. Adjuvant chemotherapy is not widely accept-
ed because of the low sensitivity of gliomas to tra-
ditional anti-neoplastic agents, poor penetration 
of most drugs across the blood-brain barrier, and 
the signiﬁ cant systemic toxicity associated with 
current agents. However, a novel alkylating agent 
– temozolomide looks promising. Radiotherapy 
of low grade gliomas is a controversial issue. 
Subgroups of patients with low-grade gliomas 
and poor prognostic factors are more likely to 
beneﬁ t from immediate postoperative RT, where-
as patients with low-risk disease, particularly oli-
godendrogliomas, can reasonably be left for ob-
servation only. However, one cannot exclude the 
possibility that delayed RT may result in a wors-
ening of long-term clinical outcome [26]. In the 
opinion of Marimanoff and Stup [27], postoper-
ative RT should not be administered routinely to 
patients with low-grade gliomas. If RT is deemed 
necessary, as is the case in progressive or inoper-
able disease causing neurological symptoms, a to-
tal dose of ≤50 Gy, with a fractional dose of ≤1.8 
to 2 Gy, should be administered using modern, 
highly conformal techniques. Among patients who 
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undergo biopsy only, and not total resection, a 
greater radiation dose can signiﬁ cantly improve 
survival, with a threshold at approximately 54 Gy 
[26]. Our data may conﬁ rm the above, because 
in our series patients receiving total doses great-
er than 56 Gy (cut off point) survived signiﬁ cant-
ly better than those receiving dose <56 Gy. Other 
studies have shown that radiation doses ≥60 Gy 
confer a survival advantage in high grade gliomas 
[8], although another study [7] has also shown 
that even dose escalation, with three dimensional 
conformal radiation to 90 Gy, cannot prevent lo-
cal failures in high-grade gliomas. Moreover, the 
current data provide no arguments for the use of 
accelerated RT, as found by Nieder [28] in meta 
analysis. On the other hand, a meta-analysis per-
formed by Steward [29] has demonstrated a small 
but consistent improvement in the survival of ap-
proximately 5–10% at 1 and 2 years, in patients 
with high-grade gliomas who received adjuvant 
chemotherapy in addition to RT.
Among patients who underwent surgical resec-
tion of their tumours and who were treated with 
RT, survival is most strongly linked to the tumour 
grade, which largely agrees with other studies. 
Patients with grade III or IV tumours had a signif-
icantly worse prognosis than those with grade I or 
II tumours. In the univariate analysis, BrdUrd LI 
also appeared to be a signiﬁ cant prognostic factor 
in terms of survival, however this parameter was 
dependent on tumour grade, and this was proba-
bly why it lost its signiﬁ cance in multivariate anal-
ysis. Patients receiving conventional RT survived 
signiﬁ cantly better than those treated with hypo- 
and accelerated RT. However, it should be stressed 
that the former method was applied mostly to low-
grade gliomas. Therefore, it cannot be excluded, 
that tumour grade, and not the RT schedule, af-
fects survival more signiﬁ cantly.
In the Cox analysis, where all biological and clini-
cal parameters were considered, age, high tumour 
grade and RT schedule appeared to be the only 
factors inﬂ uencing survival. This revealed again, 
that in the case of such tumour types, the histolog-
ical grade is the strongest biological factor inﬂ u-
encing the prognosis. When we performed sepa-
rate analyses for 2 patient subgroups differing in 
age, the proliferation rate and conventional or 
hypofractionated RT became important prognos-
tic factors for younger patients (<50 years) while 
none of the analyzed parameters was important for 
elderly patients. The dependencies obtained may 
conﬁ rm the ﬁ ndings of Fisher [21] and Rodrigues 
Pereira et al. [18] who analyzed proliferation rates 
based on Ki-67 LI and revealed that it is a useful 
predictor, although dependent on other prognos-
tic factors, particularly age. Therefore, although 
multivariate analysis is the most useful tool to eval-
uate prognostic factors and to construct appro-
priate statistical models, it is important to keep in 
mind that these models are sensitive to the vari-
ables chosen, deﬁ nitions of those variables, and 
statistical methodology.
Nevertheless, the assessment of all unfavourable 
prognostic factors in the glioma patients subjected 
to surgery and postoperative RT, may give grounds 
for applying proper RT schedules. Treatment with 
radiation or chemotherapy should not be intro-
duced until malignant transformation or faster 
growth indicators are found.
CONCLUSIONS
1. For astrocytic gliomas treated with surgery and 
radiotherapy (RT) the most signiﬁ cant prognos-
tic factors are: young age (≤50 years), low-grade 
(AI & AII), and – possibly – the RT schedule.
2. To improve RT results, younger patients (≤50 
years) with faster proliferating tumours (BrdUrd 
LI >2.1%) should receive more aggressive treat-
ment.
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